Sector News

Bayer's 2016 pharma growth Monsanto risks

February 23, 2017
Life sciences

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. Prescription drug sales expanded by 8.7% last year, to €16.4 billion, the company said in its annual earnings release, and once again, its usual suspects are behind the surge.

The boost from Bayer’s top-performing meds, plus increases in consumer health (3.5%) and animal health (4.8%) sales, pushed the German company’s total healthcare-related revenue above €22 billion.

What’s ahead for the burgeoning healthcare business—that’s the question. Though Bayer has put up a solid growth forecast for those units in 2017, sales-wise, and pledges to boost margins in all three, analysts worry that the company’s focus on its Monsanto buyout will drain away resources. The company might not have the capital to put into R&D programs like those that produced the blockbuster anticoagulant Xarelto and vision treatment Eylea, they worry.

The Monsanto deal marks a “lost opportunity to develop the pharma pipeline,” Bernstein analyst Ronny Gal wrote last year, noting that “Bayer does not have the funds to invest in both Ag and Pharma at the same time.”

That’s ironic, considering the billions that those drugs have been ginning up for the company over the past few years. Take Xarelto, for one, which Bayer sells outside the U.S. It grew by 30% last year, in currency-adjusted terms, thanks to higher script numbers in Europe and Japan. The German company also collected bigger licensing revenues on the drug from U.S. partner Johnson & Johnson. Total? Almost €3 billion. Eylea, for its part, delivered €1.62 billion, up 32%.

Together, those two drugs and three other newer Bayer meds—colon cancer med Stivarga, prostate cancer radiotherapy Xofigo and pulmonary arterial hypertension remedy Adempas—are expected to add up to €6 billion this year.

But beyond that, Bayer faces pressure on its hemophilia franchise as other drugmakers roll out competing products, and it’s been a reliable revenue-generator. Kogenate/Kovaltry, for instance, brought in blockbuster-plus sales for 2016—flat year-over-year. Its older multiple sclerosis drug is also on the decline as it loses exclusivity in various markets and faces new competition, with sales down more than 10% to €734 million. Nexavar, which still brings in hefty sales—€830 million for the year—faces a patent loss in 2020 and might have to deal with generics sooner if challenger Mylan has its way.

And Stivarga itself is seeing declines. A new rival, Lonsurf from Japanese drugmaker Otsuka, was approved in October 2015, and it has since played a part in eroding Stivarga sales. Last year, the Bayer med took a 12% drop, to €275 million.

Right now, Bayer doesn’t have much in the way of new candidates to come in and back up Xarelto when that drug goes off patent in 2024, much less Nexavar.

In short, Bayer will need R&D investment on the pharma side to beef up healthcare sales in the long term. Consumer health, which Bayer had hoped to push after buying Merck & Co.’s unit in 2014, and animal health may be growing, but much more slowly than pharma.

BMI Research’s Craig Smith is another analyst worried that Bayer won’t be able to deliver enough new drugs in the coming years. Smith has pointed out that the company already spends less than its Big Pharma peers do on R&D. With that in mind, the Monsanto “deal could significantly weaken” Bayer’s “capacity to grow within the pharmaceuticals space.”

Bayer’s top-selling drugs have kept the company on a positive trajectory in recent years. Letting its pipeline falter because it’s spending money and time on a cCrop science merger would be a long-term mistake.

By Tracy Staton

Source: Fierce Pharma

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.